Eli Lilly Integrates Zepbound and Foundayo Into Hims & Hers, Completing Cash-Pay GLP-1 Platform
Eli Lilly formally joined rival Novo Nordisk inside the Hims & Hers platform on Friday, announcing a commercial partnership that lets patients consult a licensed provider, receive a prescription, and have one of two FDA-approved weight-loss drugs …